BSF Enterprise shares moved up 10.3%, to close Tuesday's session at 1.71p, after giving investors a strategy update that flagged a world‑first T‑Rex Leather auction in Paris, and outlined a subsidiary spin‑out pathway ahead of clinical and commercial catalysts.
It comes as the company prepares to offer a tanned T‑Rex Leather™ skin fashioned into a designer handbag at an auction in Paris on 11 June.
Kerato has advanced its LiQD Cornea™ hydrogel into active veterinary Phase 1 trials that began in Q1 2026, with roughly 50% of trial funding from Canadian government grants, a midpoint reached in its PSO‑funded development programme, a pre‑ITA engagement with Health Canada and deployment of an ISO 13485 quality management system, BSF noted.e
It is aiming to sign commercial distribution agreements in Q4 2026 and target first commercial veterinary sales in early 2027, with human trial applications planned across 2026-2027 and a subsidiary‑level spin‑out planned post‑catalyst.
3D Bio‑Tissues (3DBT) has commercially launched CytoBoost™ REVIVE media into biopharma, expanded City‑MixR sales into the cultivated meat sector, reported significant growth in customer orders over a recent three‑month period and secured a supply agreement with Seawith that underpins an active £500,000 pipeline.
The board described 2026 as a critical transition year from R&D to commercialisation, citing three distinct high‑growth subsidiaries, simultaneous infrastructure upside and an anti‑dilutive spin‑out financing strategy under active evaluation.
